Abstract
High-dose prednisolone may not be superior to a low-dose 6-week regimen in improving clinical, physiological and radiological outcomes, or health-related quality of life, in patients with symptomatic post-COVID-19 diffuse parenchymal lung abnormalities https://bit.ly/32zqnXt
Trial registration: ClinicalTrials.gov NCT04657484 .
All Keywords
【초록키워드】 outcomes, symptomatic, low-dose, Patient, Quality of life, physiological, Prednisolone, regimen, radiological, lung abnormality, parenchymal, 【제목키워드】 Trial, Open-label, lung, Randomised trial, low-dose prednisolone, parenchymal, symptomatic patient,
【초록키워드】 outcomes, symptomatic, low-dose, Patient, Quality of life, physiological, Prednisolone, regimen, radiological, lung abnormality, parenchymal, 【제목키워드】 Trial, Open-label, lung, Randomised trial, low-dose prednisolone, parenchymal, symptomatic patient,